Table 1 Patient demographic and clinical characteristics (surgery group vs. non-surgery group)

Age, yrs; mean

59.9

63.1

0.6

Subtype:

0.047

 Luminal

30 (50%)

46 (57.5%)

 Luminal HER2

4 (6.7%)

9 (11.3%)

 Her2

19 (31.7%)

10 (12.5%)

 Triple negative

7 (11.7%)

14 (17.5%)

Metastasis statuses: *

1) By metastatic number in each organ

0.002

Oligo

25 (41%)

36 (59%)

 Bone

7

9

 Lung

11

2

 Liver

2

0

 Brain

1

0

 Lymph node

4

2

Visceral

14 (17.5%)

66 (82.5%)

 Lung

15

10

 Liver

8

25

 Pleural dissemination

6

14

 Peritoneal dissemination

0

6

 Brain

5

2

 Meningeal dissemination

6

1

 Other

2

5

2) By number of metastatic organs in visceral cases

0.22

Within single organ

8(22.2%)

21(31.8%)

Spread to multiple organs (≥ 2)

28(77.8%)

45(68.2%)

Systemic therapy:

< 0.0001

No. of treatment regimens:

 1

13 (21.3%)

29 (36.2%)

 2

21 (34.4%)

17 (21.2%)

 ≥ 3

16 (26.2%)

27 (33.7%)

Regimen:

Chemotherapy

14 (23.3%)

29 (36.7%)

 Anthracycline

1

1

 Taxane

11

21

 Anthracycline + taxane

26

15

 Anti-Her2 therapy

27

16

 Immune checkpoint inhibitor

0

2

 Other

9

16

Endocrine

5 (8.3%)

27 (34.2%)

 Aromatase inhibitor

16

31

 Tamoxifen

3

12

 Fulvestrant

1

17

 C + E

38 (63.3%)

17 (21.5%)

 None

3 (5%)

6 (7.56%)

Best therapeutic response:

< 0.0001

 CR

7 (17.5%)

1 (1.32%)

 PR

15 (37.5%)

8 (10.5%)

 SD

17 (42.5%)

4 (5.3%)

 PD

1 (2.5%)

42 (55.3%)

Surgery:

None

 Partial mastectomy

8 (13.1%)

 Mastectomy

51 (83.6%)

 Other

2 (3.27%)

Axillary dissection:

 Yes

55 (90.1%)

 No

4 (6.55%)

Surgical margin:

None

 Positive

5

 Negative

27

Pre ALC, /µL; mean

1,626

1,674

0.21

NLR, mean:

 Pre

2.94

3.62

0.19

 6 mos.

3.18

2.86

0.94

 1 yr

2.95

2.42

0.54

 2 yrs

2.5

2.58

0.56